February 17th 2024
A study suggests that a novel CAR T-cell therapy could be a curative treatment for some patients with chronic lymphocytic leukemia, with 25% of responders still in remission after 6 years.
Medical Crossfire®: How Have HER2-Low Expressing Breast Cancers and Novel Advances in the Field Redefined Care As We Knew It?
View More
Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?
View More
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Show Me Your Care Plan: Nursing Considerations for Managing Breast Cancer Patients
View More
Community Practice Connections™: The Newest Frontier in HR+ Breast Cancer—Targeting ESR1 Mutations with Next-Generation Endocrine Therapy
View More
Clinical Case Vignette Series™: 40th Annual Miami Breast Cancer Conference®
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
HER2+ Breast Cancer Tumor Board: Navigating Current and Evolving Strategies from Early Stages to Metastases
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Show Me the Data®: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® West
July 12-13, 2024
Register Now!
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Community Practice Connections®: Evaluating the Evolving Treatment Landscape for mHR+ Breast Cancer-How to Personalize Care and Improve Patient Outcomes
View More
Community Practice Connections™: Leveraging Multidisciplinary Teams in Early-Stage Breast Cancer When the Goal Is Cure
View More
Community Practice Connections™: 22nd Annual International Congress on the Future of Breast Cancer®
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
22nd Annual School of Breast Oncology
November 7-9, 2024
Register Now!
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
IMpassion130 Data Demonstrate Clinical Benefit for Immunotherapy in Metastatic TNBC
December 18th 2018Leisha A. Emens, MD, PhD, professor of medicine at the UPMC Cancer Center, discusses how the data from the IMpassion130 trial have demonstrated benefit for immunotherapy in metastatic triple-negative breast cancer.
Watch
Overcoming Resistance to Immunotherapy Requires Advanced Strategies
December 11th 2018Primary and acquired resistance to immunotherapy necessitates novel strategies that can overcome cellular processes and genetic mutations of resistance to advance into the next age of cancer therapy.
Read More
No Survival Benefit Found With Durvalumab in Head and Neck Cancer
December 10th 2018AstraZeneca has reported that the phase III EAGLE trial has missed its primary endpoint, as patients with recurrent or metastatic head and neck squamous cell carcinoma who progressed after platinum-based chemotherapy did not see a survival benefit with durvalumab alone or combined with tremelimumab.
Read More
FDA Grants Atezolizumab Plus Chemotherapy Regimen Priority Review for Frontline SCLC
December 5th 2018Based on findings from the phase III IMpower133 study, a supplemental biologics license application (sBLA) for atezolizumab (Tecentriq) has been granted a priority review by the FDA for use in combination with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer.
Read More
I-O Combo of Checkpoint Inhibitor With CAR T-Cell Therapy Shows Promise in Relapsed B-Cell ALL
December 3rd 2018According to results from a small clinical study, checkpoint inhibitors in combination with chimeric antigen receptor T-cell therapy showed promise for improving CAR T-cell persistance in some patients with relapsed B-cell acute lymphoblastic leukemia. <br />
Read More
Daratumumab With VRd Induced VGPR in 100% of Patients With Multiple Myeloma
December 3rd 2018In a study of transplant-eligible patients with newly diagnosed multiple myeloma, daratumumab added to bortezomib, lenalidomide, and dexamethasone induced at least a very good partial response in all patients, including a complete response in 63% of patients, at the end of consolidation therapy.<br />
Read More
Risk of Relapse Reduced With HCT Following CAR T-Cell Therapy in ALL
December 2nd 2018Patients with acute lymphoblastic leukemia saw a reduction in the risk for recurrence after receiving a stem cell transplant for the first time following treatment with CD19 chimeric antigen receptor T-cell therapy.
Read More
High Response Rate Found in CLL With Ibrutinib/CAR T-Cell Combo
December 2nd 2018According to a retrospective phase I/II study, over 80% of patients with relapsed or refractory chronic lymphocytic leukemia responded to concurrent treatment with ibrutinib and the CD19-targeted chimeric antigen receptor CAR T-cell therapy, JCAR014.<sup>1</sup> Findings from this study were presented at the 60th American Society of Hematology Annual Meeting.
Read More
Antibiotics Reduce ICI Efficacy for Patients With Urological Cancers
November 30th 2018Patients with metastatic renal and urothelial bladder cancer who receive antibiotics concomitantly with immune checkpoint inhibitors have shorter progression-free survival and overall survival rates than patients who do not, according to a poster presented at the European Congress on Immunotherapies in Cancer™ conference, hosted by Physicians’ Education Resource®, LLC, September 21 and 22, 2018, in Barcelona, Spain.
Read More
Vedolizumab Induces Remission of Immunotherapy-Related Diarrhea, Colitis
November 29th 2018Vedolizumab induced clinical, endoscopic, and histologic remission of steroid-refractory, immune-mediated enterocolitis in patients receiving immune checkpoint inhibitorsfor cancer treatment, according to the results of a small retrospective study presented at the 2018 American College of Gastroenterology Annual Meeting.
Read More
TGF-BR1 Inhibitor Shows Early Activity and Tolerability in Advanced Cancers
November 26th 2018Treatment of patients with advanced or metastatic cancers with the transforming growth factor-β receptor type 1 inhibitor LY3200882 demonstrated a tolerable safety profile and early signs of efficacy, according to the results from a first-in-human, dose-escalation phase I trial presented at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer.
Read More
Atezolizumab Shows Activity in Alveolar Soft Part Sarcoma
November 22nd 2018Patients with advanced alveolar soft part sarcoma demonstrated durable responses that occurred early following the initiation of atezolizumab, according to phase II trial findings presented at the 2018 CTOS Annual Meeting. Atezolizumab was also well tolerated and demonstrated a favorable safety profile.
Read More
Durvalumab Combo Falls Short in Frontline Metastatic NSCLC
November 17th 2018Using durvalumab (Imfinzi) combined with tremelimumab for the frontline treatment of patients with metastatic non–small cell lung cancer did not result in a statistically significant improvement in overall survival compared to standard chemotherapy, according to a press release from AstraZeneca.
Read More
Combination Therapy With Mogamulizumab Demonstrates Tolerable and Manageable AEs
November 12th 2018Results from a two-part, phase I dose-escalation and -expansion trial involving mogamulizumab in combination with durvalumab or tremelimumab for the treatment of patients with advanced solid tumors demonstrated mild-to-moderate adverse events that were tolerable and manageable, according to Dmitriy Zamarin, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, during his presentation at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer.
Read More
Computer Analysis Determines Best Practices for Use of Tumor Mutational Burden in Patient Care
November 10th 2018In an effort to determine best practices and ensure consistent clinical interpretation of tumor mutational burden assessment for patients with cancer, a group of diagnostic test partners conducted an in silico analysis and found that panel-derived TMB strongly correlated with whole-exome sequencing data provided from The Cancer Genome Atlas.
Read More
Personalized Immunotherapy Regimens Hinge on the Discovery of Effective Biomarkers, Expert Says
November 9th 2018Personalized immunotherapy regimens for patients with cancer is a long-term goal of the immuno-oncology field, yet progress toward this goal necessitates the discovery of an effective biomarker for guiding treatment decision making, according to Jason Luke, MD.
Read More
Engineered Anti-MAGE-A T-Cells Show Promise in Preliminary Data
November 5th 2018According to first-in-human findings reported in a poster presentation during the ESMO Annual Congress, genetically engineered T-cells targeting melanoma-associated antigen-A4 appeared safe and demonstrated some evidence of antitumor activity.
Read More
Tepotinib Plus Gefitinib Demonstrates PFS Improvement Versus Chemotherapy in MET+ EGFR-Mutant NSCLC
October 31st 2018Both progression-free survival and overall response were improved in patients with <em>MET</em> mutated <em>EGFR</em>-positive non–small cell lung cancer resistant to prior EGFR TKI therapy who were treated with tepotinib plus gefitinib compared with chemotherapy. These phase II findings were presented at the 2018 ESMO Congress.
Read More
OS Benefit Seen in Nonsquamous NSCLC With Triplet Regimen in IMpower130
October 23rd 2018Results from the phase III IMpower130 trial demonstrated a statistically significant improvement in both progression-free survival and overall survival with a triplet regimen of atezolizumab, carboplatin, and nab-paclitaxel compared with chemotherapy alone in patients with previously untreated stage IV nonsquamous non–small cell lung cancer.
Read More
FDA Adds 3 Months to Review Period for Nivolumab Plus Ipilimumab for TMB-High NSCLC
October 23rd 2018Three months have been added on by the FDA to the review period for the supplemental biologics license application for the frontline treatment combination of nivolumab plus low-dose ipilimumab for patients with advanced non–small cell lung cancer with tumor mutational burden ≥10 mutations per megabase.
Read More
Frontline Atezolizumab and Nab-Paclitaxel Demonstrate PFS Benefit in PD-L1+ mTNBC
October 20th 2018The combination of atezolizumab and nab-paclitaxel demonstrated a 2.5-month benefit in progression-free survival over nab-paclitaxel alone in patients with PD-L1–positive metastatic triple-negative breast cancer, according to findings of the phase III IMpassion130 trial presented at the 2018 ESMO Congress.
Read More
Antiangiogenics and Immunotherapy Combos Show Promising Activity in Solid Tumors
October 18th 2018Investigators have long known that the combination of antiangiogenic agents and immunotherapy could enhance antitumor response and improve outcomes for patients with certain cancers. But recently, this old idea has become the focus of new research in diseases such as hepatocellular carcinoma, urothelial carcinoma, and endothelial cancer.
Read More
Use of Tumor-Infiltrating Lymphocytes Expanding in Breast Cancer
October 16th 2018The role of tumor-infiltrating lymphocytes (TILs) is expanding in cancer care, necessitating a more involved role for pathologists to quantify immune infiltrates, K.P. Siziopikou, MD, PhD, suggested during a presentation at the 2018 Lynn Sage Breast Cancer Symposium.
Read More
Role of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Oncogenic Driver Mutations
October 11th 2018Lung and bronchus cancer are the leading causes of cancer-related deaths in the United States and will be responsible for an estimated 154,050 American deaths in 2018. An estimated 234,030 new cases of lung and bronchus cancer will be diagnosed in 2018, which represents 13.5% of all new cancer diagnoses in the United States.
Read More
Biomarkers, Novel Combinations Key to Improving Response to Immunotherapy
October 10th 2018In a roundtable discussion at the 2018 International Cancer Immunotherapy Conference, Nobel Prize Winner James P. Allison, MD, and other experts discussed the research that is still necessary to bring immunotherapy response rates to 100%.
Read More